Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial.
Background Cryptococcosis is a leading cause of death among people with human immunodeficeincy virus (HIV). Guidelines recommend combination therapy with amphotericin B and flucytosine, but standard flucytosine dosing of 100 mg/kg/day is associated with hematologic toxicity. The FLOOR trial investig...
| Published in: | Clinical Infectious Diseases Vol. 82; no. 1; pp. 67 - 75 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | clinical trial research tables/charts Journal Article |
| Published: |
Oxford University Press / USA
1/15/2026
|
| Online Access: | View this record in EBSCOhost |